Watson launches generic painkiller

Drug maker receives FDA approval for generic version of Actavis' Kadian

PARSIPPANY, N.J. — Watson Pharmaceuticals has launched its generic version of an opioid drug for treating pain, the company said Thursday.

Watson announced the Food and Drug Administration approval and launch of morphine sulfate extended-release capsules.

The drug is a generic version of Actavis' Kadian, which had sales of about $275 million during the 12-month period ended in September, according to IMS Health.

Interested in this topic? Sign up for our weekly Retail Health Provider e-newsletter.

Login or Register to post a comment.